Xiamen Amoytop Biotech Co., Ltd. (688278.SS)
CNY 78.14
(2.0%)
CNY 78.14
(2.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 555.44 Million CNY | 93.52% |
| 2022 | 287.01 Million CNY | 58.4% |
| 2021 | 181.2 Million CNY | 55.44% |
| 2020 | 116.56 Million CNY | 81.31% |
| 2019 | 64.29 Million CNY | 301.76% |
| 2018 | 16 Million CNY | 209.62% |
| 2017 | 5.16 Million CNY | -82.37% |
| 2016 | 29.31 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 128.8 Million CNY | -30.95% |
| 2024 Q3 | 249.8 Million CNY | 42.31% |
| 2024 Q2 | 175.53 Million CNY | 36.28% |
| 2023 Q4 | 186.54 Million CNY | 11.88% |
| 2023 FY | 555.44 Million CNY | 93.52% |
| 2023 Q3 | 166.72 Million CNY | 41.29% |
| 2023 Q1 | 84.17 Million CNY | -2.82% |
| 2023 Q2 | 118 Million CNY | 40.19% |
| 2022 Q1 | 57.45 Million CNY | 7.36% |
| 2022 FY | 287.01 Million CNY | 58.4% |
| 2022 Q4 | 86.61 Million CNY | 29.76% |
| 2022 Q3 | 66.75 Million CNY | -12.4% |
| 2022 Q2 | 76.2 Million CNY | 32.63% |
| 2021 Q3 | 55.58 Million CNY | 46.71% |
| 2021 Q4 | 53.51 Million CNY | -3.73% |
| 2021 Q2 | 37.88 Million CNY | 10.72% |
| 2021 Q1 | 34.21 Million CNY | -15.11% |
| 2021 FY | 181.2 Million CNY | 55.44% |
| 2020 Q4 | 40.3 Million CNY | 35.94% |
| 2020 Q1 | 22.35 Million CNY | 0.68% |
| 2020 Q2 | 24.25 Million CNY | 8.46% |
| 2020 Q3 | 29.65 Million CNY | 22.26% |
| 2020 FY | 116.56 Million CNY | 81.31% |
| 2019 Q1 | 542.13 Thousand CNY | -96.51% |
| 2019 FY | 64.29 Million CNY | 301.76% |
| 2019 Q4 | 22.2 Million CNY | -16.31% |
| 2019 Q3 | 26.53 Million CNY | 76.86% |
| 2019 Q2 | 15 Million CNY | 2667.76% |
| 2018 Q3 | 16.46 Million CNY | 0.0% |
| 2018 Q4 | 15.52 Million CNY | -5.7% |
| 2018 FY | 16 Million CNY | 209.62% |
| 2017 FY | 5.16 Million CNY | -82.37% |
| 2016 FY | 29.31 Million CNY | 0.0% |